McNamara Robert 4
4 · AVITA Medical, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
AVITA Medical (RCEL) Director Robert McNamara Receives Awards
What Happened
Robert McNamara, a director of AVITA Medical, received equity awards reported on Form 4. The filing shows 22,214 restricted stock units (RSUs) and a grant of 16,133 stock options. No cash was paid to receive these grants; the option exercise price is $3.77 per share (the Nasdaq closing price on the grant date).
Key Details
- Transaction dates: grant date listed as January 20, 2026; these awards were subject to and received stockholder approval on June 3, 2026. Form 4 filed June 4, 2026.
- RSUs: 22,214 RSUs — each RSU represents a contingent right to one share; vesting occurs 12 months after the January 20, 2026 grant date (i.e., Jan 20, 2027). (Footnote F1)
- Options: 16,133 options granted to acquire 16,133 shares at $3.77 per share (grant recorded as a derivative award, not an exercise). (Footnote F3)
- Cash/consideration: Filing shows $0 paid at grant (awards issued, not purchased or exercised).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Includes unvested RSUs (Footnote F2).
- Timeliness: awards were originally granted Jan 20, 2026 but were contingent on shareholder approval obtained June 3, 2026; the Form 4 was filed the following day.
Context
These entries are awards (grant of RSUs and options), not open-market purchases or exercises. RSUs convert to actual shares only upon vesting (here, 12 months from the grant date), and options give the right to buy shares at $3.77 per share in the future if the holder exercises them. Awards approved by stockholders are routine compensation for directors and do not, by themselves, indicate immediate buying or selling of shares.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-01-20+22,214→ 108,985 total - Award
Stock Options (Right to Buy)
[F3]2026-01-20+16,133→ 16,133 totalExercise: $3.77From: 2027-01-20Exp: 2036-01-20→ Common Stock (16,133 underlying)
Footnotes (3)
- [F1]Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- [F2]Includes unvested RSUs.
- [F3]On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.